Investment Rating - The industry investment rating is "Recommended" [1] Core Insights - The report highlights the impact of escalating trade conflicts on the supply chain of pharmaceuticals, particularly regarding the exemption of certain drugs from tariffs, which reflects the U.S.'s reliance on global pharmaceutical supply chains [3] - The report emphasizes the importance of international markets for Chinese pharmaceutical exports, with a projected export value of $107.96 billion in 2024, indicating a growth of 5.9% year-on-year [4] - The report discusses the potential changes in the supply landscape for blood products due to new tariffs, which may accelerate domestic substitution opportunities [6] - The report notes the ongoing evolution of raw material applications, particularly in the nicotine sector, as companies explore new production avenues [8] - The report indicates that the optimization of centralized procurement policies may alleviate pricing pressures on traditional pharmaceutical companies [10] - The report outlines advancements in CAR-T cell therapies, with significant sales growth and the potential for cost reductions in the future [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.57 percentage points in the past week, ranking third among 31 primary industry indices [23] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has shown a 3.15% increase over the past month, outperforming the CSI 300 index by 4.20 percentage points [40] - The current PE (TTM) for the pharmaceutical sector is 31.25, which is below the historical average of 32.95 [45] 3. Recent Research Achievements - The report lists various deep-dive studies conducted by the research team, focusing on supply and demand dynamics in the blood products sector and the impact of policy support on inhalation drug markets [49] 4. Important Industry Policies and News - Recent policy updates include the release of the 2025 edition of the Pharmacopoeia of the People's Republic of China, which will take effect on October 1, 2025 [52] - Significant industry news includes the approval of new drug applications by major pharmaceutical companies, indicating ongoing innovation and market activity [54][55]

血制品概念7日盘中集体上扬，截至发稿，博晖创新（300318）涨超12%，博雅生物（300294）涨超 10%，派林生物（000403）、卫光生物（002880）涨停，天坛生物（600161）涨近9%，华兰生物 （002007）涨超5%。 该机构表示，血制品生产涉及国家生物安全且具备资源品属性，由于政策限制，目前行业内仅存较少厂 商，形成了以天坛生物、上海莱士（002252）、华兰生物、派林生物等为主的寡头格局，产业链自主可 控，受海外地缘政治风险影响较小。随着血制品行业内多个企业股东实力的持续提升，优质血制品资产 的竞争力将持续提升，战略发展路径将更加清晰，未来中国有望出现多个具备全球竞争力的血制品巨 头。在贸易摩擦背景下，血制品行业具备内循环性质，外部贸易政策对我国血制品行业自身发展负面影 响较小，看好其长远发展。 机构表示，血制品市场需求较为刚性，加征关税可能会造成短期进口白蛋白价格上涨，利好国产企业。 光大证券指出，血制品可治疗多种疾病，需求端受经济周期影响小，呈现刚性需求属性，贸易摩擦对需 求影响有限。另外，血制品具备资源属性，受上游原材料血浆供应影响，整体市场供给有限。我国约有 60%以上的人血白 ...

Investment Rating - The report suggests a positive outlook for the pharmaceutical industry, indicating a potential for outperformance compared to the overall market [27]. Core Insights - The report highlights the impact of the recent U.S. tariff measures, which include a 34% additional tariff on Chinese goods, and the subsequent Chinese countermeasures that may benefit domestic pharmaceutical companies [3][4][5]. - It emphasizes the growth in China's pharmaceutical exports, particularly to the U.S., which reached $19.05 billion in 2024, marking an 11.7% increase year-on-year [6][7]. - The report identifies specific sectors within the pharmaceutical industry that may benefit from the tariff situation, including blood products, high-end raw materials, medical devices, and innovative drugs [18][19]. Summary by Sections Tariff Impact - The U.S. has implemented a 34% tariff on Chinese goods, which affects a wide range of medical supplies and devices, while China has responded with similar tariffs on U.S. imports [4][5]. - The tariffs are expected to disrupt the supply of imported blood products, potentially increasing demand for domestic alternatives [18]. Trade Statistics - In 2024, China's total pharmaceutical trade amounted to $199.376 billion, with exports at $107.964 billion and imports at $91.412 billion, showing a slight decline in imports but a recovery in exports [6][11]. - The U.S. remains the largest market for Chinese pharmaceutical exports, accounting for 17.6% of total exports [7][11]. Sector Opportunities - Blood Products: The tariff on U.S. imports may lead to increased domestic production and sales of blood products, with companies like Tian Tan Biological, Hualan Biological, and others positioned to benefit [18]. - High-End Raw Materials: The report suggests that domestic manufacturers of critical raw materials and consumables may gain market share due to reduced competition from U.S. imports [18]. - Medical Devices: Companies focusing on high-value medical devices are recommended for their potential to capture market share from imported products [18]. - Innovative Drugs: The report encourages investment in companies involved in the development of innovative drugs, particularly those that can replace U.S. imports in oncology and vaccine sectors [19].

- The report utilizes the **Heston model** to calculate the implied volatility of near-month at-the-money options, which serves as the market's fear index. Implied volatility reflects market participants' expectations of future volatility[7] - The **broad-based timing strategy** signals are based on the shape analysis of indices. For example, the Shanghai 50 index shows a bullish signal, while other broad-based indices remain neutral. The strategy's annualized return for the Shanghai 50 index is 11.84%, with a maximum drawdown of -20.2%[12][14] - The **industry timing strategy** is constructed using the long-short ratio scissors difference of industry index constituent stocks. If no bullish or bearish signals are present on a given day, the scissors difference and its ratio are set to zero. This model outperforms its respective industry indices in all cases, demonstrating excellent historical backtesting performance[15] - The **special bullish shape signals** are derived from six technical patterns: Golden Needle Bottom, Rocket Launch, Full Red, Hanging Line, Paradise Line, and Dark Cloud Line. Among these, Golden Needle Bottom, Rocket Launch, and Full Red exhibit strong positive predictive effects. Specific stocks with these signals include Shenzhen Energy, Pailin Biotech, and others[20][21][22] - The **brokerage golden stock shape signals** combine fundamental analysis with shape analysis. Stocks recommended by brokerages are monitored for shape-based buy signals, and a portfolio is constructed by buying on the second trading day after the signal appears. This approach significantly improves portfolio returns and reduces maximum drawdowns. Stocks with a 70% bullish signal success rate this week include Lens Technology and Haitian Precision[28][29][33]

Core Viewpoint - The strategic cooperation agreement between Palin Bio (000403) and XtalPi Holdings Limited aims to enhance innovation and quality management in the blood products industry through collaboration in product development and intelligent management solutions [1][2]. Group 1: Strategic Cooperation Details - The cooperation focuses on three main areas: drug research and optimization, intelligent management of drug production and quality, and protein structure and function research [1]. - The partnership will leverage Palin Bio's expertise in blood products and XtalPi's strengths in artificial intelligence to align with national strategies for integrating AI with the real economy and enhancing regulatory oversight in the blood products sector [2]. Group 2: Impact on Financials - The signing of the framework agreement is not expected to have a significant impact on the current financial status and operating performance of Palin Bio, with future effects dependent on the implementation of specific cooperation projects [2].

证券代码：000403 证券简称：派林生物 公告编号：2024-067 派斯双林生物制药股份有限公司 关于公司部分董监高及核心管理人员 增持公司股份计划的公告 1、计划增持主体：公司现任总经理荣先奎、监事会主席郭麾、董事兼副总经理 黄晓英、董事兼副总经理司文彬、董事兼副总经理叶兰、监事左超、董事会秘书赵 玉林、财务总监王晔弘，公司全资子公司广东双林生物制药有限公司（以下简称"广 东双林"）总经理闫晨。 1 截至本公告披露日，董事会秘书赵玉林持有公司股份 163,956 股，财务总监王 晔弘持有公司股份 85,188 股，董事兼副总经理司文彬持有公司股份 200 股，合计持 有公司股份 249,344 股，占本公司总股本的 0.0341%。 2、本次增持主体在本公告披露之前12个月内未披露增持计划。 3、本次增持主体在本公告前6个月均未减持公司股份。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、派斯双林生物制药股份有限公司（以下简称"公司"）于近日收到公司部分董 监高及核心管理人员自愿增持公司股份计划的通知，基于对公司未来发展前景的信 心以及 ...

证券代码：000403 证券简称：派林生物 公告编号：2024-058 派斯双林生物制药股份有限公司 关于桦南县派斯菲科单采血浆有限公司和肇东市派斯菲科 单采血浆有限公司获得单采血浆许可证的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）全资子公司哈尔滨派斯 菲科生物制药有限公司下属桦南县派斯菲科单采血浆有限公司和肇东市派斯菲科单 采血浆有限公司收到黑龙江省卫生健康委员会签发的《单采血浆许可证》，现将主 要信息公告如下： 一、桦南县派斯菲科单采血浆有限公司 机构名称：桦南县派斯菲科单采血浆有限公司 地址：桦南县经济开发区双果路与丰盛街交口 业务项目：采集健康人普通血浆和特免血浆 采浆区域（范围）：佳木斯市、七台河市、双鸭山市和鹤岗市所辖的区、县及 县级市 登记号：MA1C6J62923000016F2009 有效期：2024年10月28日至2026年10月27日 该单采血浆站经核准登记，准予执业。 二、肇东市派斯菲科单采血浆有限公司 机构名称：肇东市派斯菲科单采血浆有限公司 地址：肇东市北部新区移动公司北侧、 ...

Financial Performance - Revenue for the third quarter reached 754.09 million yuan, a year-on-year increase of 13.27%[3] - Net profit attributable to shareholders of the listed company was 215.75 million yuan, up 17.86% year-on-year[3] - Total revenue for the quarter reached 1,890,265,336.27 yuan, a significant increase from 1,374,813,312.16 yuan in the same period last year[16] - Net profit for the quarter was 542,758,460.07 yuan, up from 325,813,319.79 yuan in the previous year[17] - Operating profit increased to 638,752,175.75 yuan, compared to 372,635,563.90 yuan in the prior year[17] - Comprehensive income for the period totaled 542,752,820.16 yuan, an increase from 325,834,307.14 yuan in the previous period[18] - Basic and diluted earnings per share were 0.7425 yuan, up from 0.4460 yuan in the previous period[18] Assets and Liabilities - Total assets as of the end of the reporting period were 9.05 billion yuan, an increase of 4.90% compared to the end of the previous year[3] - Total assets grew to 9,053,216,302.97 yuan, up from 8,630,474,084.53 yuan at the end of the previous quarter[13][15] - Fixed assets increased by 45.70% to 1.37 billion yuan as construction projects reached the expected usable state[6] - Fixed assets increased to 1,373,956,195.97 yuan, compared to 942,994,319.65 yuan in the previous quarter[13] - Total liabilities stood at 1,228,389,449.24 yuan, slightly higher than 1,208,610,202.73 yuan in the previous quarter[14] - Equity attributable to the parent company's shareholders increased to 7,831,710,847.17 yuan, up from 7,428,649,258.06 yuan in the previous quarter[15] Cash Flow and Investments - The company's cash flow from investment activities decreased by 78.03% to -841.55 million yuan, mainly due to increased purchases of cash management products[7] - Investment income surged by 574.51% to 29.39 million yuan due to realised gains from cash management products[7] - Cash received from sales of goods and services was 1,868,361,377.74 yuan, compared to 1,573,400,641.94 yuan in the previous period[19] - Net cash flow from operating activities was 227,534,196.54 yuan, slightly higher than 225,733,198.18 yuan in the previous period[20] - Cash received from investments was 940,000,000.00 yuan, doubling from 470,000,000.00 yuan in the previous period[20] - Net cash flow from investing activities was -841,549,214.80 yuan, a decrease from -472,711,848.24 yuan in the previous period[20] - Net cash flow from financing activities was -60,650,552.66 yuan, compared to 28,452,153.67 yuan in the previous period[20] - Net increase in cash and cash equivalents was -674,688,890.07 yuan, a decrease from -218,461,879.92 yuan in the previous period[21] - Ending cash and cash equivalents balance was 753,590,120.03 yuan, down from 781,808,629.21 yuan in the previous period[21] Research and Development - R&D expenditure increased by 36.16% to 92.10 million yuan, driven by increased capitalised R&D spending[6] - Research and development expenses decreased to 45,975,375.17 yuan, down from 53,761,401.55 yuan in the same period last year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 19,784[8] - The largest shareholder, GQC Shengbang Yinghao Investment Partnership, holds 20.97% of the shares, amounting to 153,752,812 shares[8] - The second-largest shareholder, Harbin Tongzhicheng Technology Development Co., Ltd., holds 10.97% of the shares, amounting to 80,381,128 shares[8] - The third-largest shareholder, Shenzhen Shipping Health Technology Co., Ltd., holds 4.46% of the shares, amounting to 32,694,301 shares[8] Financial Position - The company's monetary funds at the end of the period were 754,186,603.94 yuan, a decrease from 1,429,349,951.47 yuan at the beginning of the period[12] - The company's trading financial assets increased to 1,000,209,682.43 yuan from 423,337,138.12 yuan at the beginning of the period[12] - The company's accounts receivable decreased to 571,175,853.29 yuan from 583,578,747.20 yuan at the beginning of the period[12] - The company's inventory increased to 1,139,194,714.69 yuan from 909,374,530.76 yuan at the beginning of the period[12] - The total current assets at the end of the period were 3,542,327,499.32 yuan, slightly increased from 3,426,074,653.60 yuan at the beginning of the period[12] Loans and Subsidies - The company's long-term loans rose by 38.33% to 271.23 million yuan, driven by increased fixed asset loans for project construction[6] - Government subsidies received during the period decreased by 33.96% to 6.41 million yuan[6] Return on Equity - The company's weighted average return on equity (ROE) increased by 0.18 percentage points to 2.79%[3] Construction Projects - The company's investment in construction projects decreased to 463,311,557.62 yuan, down from 582,699,721.94 yuan in the previous quarter[13] Financial Expenses - The company's financial expenses showed a net benefit of -36,946,315.96 yuan, compared to -42,850,779.46 yuan in the same period last year[16]

北京市嘉源律师事务所 关于派斯双林生物制药股份有限公司 2024 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 SRE Units Saffi A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI `AN 致:派斯双林生物制药股份有限公司 北京市嘉源律师事务所 关于派斯双林生物制药股份有限公司 2024年第二次临时股东大会的 法律意见书 嘉源(2024)-04-748 北京市嘉源律师事务所(以下简称"本所")接受派斯双林生物制药股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《派斯双林生物制药股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司2024年第二次临时股东大会(以下简称"本次股 东大会"）进行见证,并依法 ...

Financial Performance - The net profit attributable to shareholders for the first three quarters of 2024 is expected to be between 521.91 million and 554.53 million CNY, representing a year-on-year growth of 60% to 70%[6]. - The net profit after deducting non-recurring gains and losses is projected to be between 485.53 million and 512.51 million CNY, indicating a year-on-year increase of 80% to 90%[6]. - Basic earnings per share are estimated to be between 0.7140 CNY and 0.7587 CNY, compared to 0.4460 CNY in the same period last year[4]. - For the third quarter of 2024, the net profit attributable to shareholders is expected to be between 201.36 million and 228.82 million CNY, reflecting a year-on-year growth of 10% to 25%[5]. - The net profit after deducting non-recurring gains and losses for Q3 2024 is projected to be between 190.35 million and 215.17 million CNY, with a year-on-year increase of 15% to 30%[5]. Growth Drivers - The growth in net profit is primarily driven by an increase in raw plasma collection and a favorable market demand for blood products[6]. - The company anticipates an increase in the number and sales volume of its available products for the first three quarters of 2024[6]. Financial Reporting and Risks - The financial data provided is preliminary and has not been audited by an accounting firm, with detailed financial results to be disclosed in the Q3 2024 report[7]. - The company emphasizes the importance of investors being aware of investment risks related to the preliminary financial forecasts[7]. - The designated information disclosure media for the company is the Securities Times and the CNINFO website[7].